31722-49-3

Usage

Uses

Used in Pharmaceutical Synthesis:
1H-Imidazole-2-carbonitrile serves as a crucial intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and therapeutic compounds. Its unique structure and reactivity facilitate the creation of a wide range of medicinal agents.
Used in Agrochemical Production:
In the agrochemical industry, 1H-Imidazole-2-carbonitrile is utilized as an essential intermediate, playing a significant role in the synthesis of various agrochemicals that contribute to crop protection and enhancement of agricultural productivity.
Used in Fine Chemicals Manufacturing:
1H-Imidazole-2-carbonitrile acts as a building block in the production of fine chemicals, which are high-purity chemicals used in various applications, including pharmaceuticals, fragrances, and flavorings. Its presence in these compounds ensures the quality and effectiveness of the final products.
Used in Active Pharmaceutical Ingredients (API) Development:
As a key component in the development of active pharmaceutical ingredients, 1H-Imidazole-2-carbonitrile enables the creation of innovative and effective medications, addressing unmet medical needs and improving patient outcomes.
Used in Novel Drug Discovery:
Due to its distinctive chemical properties, 1H-Imidazole-2-carbonitrile holds potential in the discovery of novel drugs and therapeutic compounds, driving advancements in medicine and healthcare.

InChI:InChI=1/C4H3N3/c5-3-4-6-1-2-7-4/h1-2H,(H,6,7)

Upstream product

• 10111-08-7 2-imidazolecarbaldehyde 
• 16093-82-6 1H-Imidazole-2-carbothioic acid amide 
• 101226-40-8 1-<<2-(trimethylsilyl)ethoxy>methyl>-1H-imidazole-2-carbonitrile 
• 46323-27-7 1-(Phenylmethyl)-1H-imidazole-2-carbonitrile 

Downstream Products

• 1185190-24-2 1-[4-(3,5-dimethylphenylsulfanyl)-5-iodo-2-methyl-6-oxo-1,6-dihydropyridin-3-ylmethyl]-1H-imidazole-2-carbonitrile 
• 46323-27-7 1-(Phenylmethyl)-1H-imidazole-2-carbonitrile 
• 1604817-73-3 (2R,5S)-5-(2-cyanoimidazol-1-ylmethyl)-4-{2-[6-(4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-pyrrolo[3,2-b]pyridin-1-yl]-2-oxo-ethyl}-2-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1434585-12-2 C₁₅H₁₃N₇O 
• 1383742-21-9 t-butyl (R)-(2-(5-bromo-2-fluorophenyl)-1-(2-cyano-1H-imidazol-1-yl)propan-2-yl)carbamate 
• 53981-69-4 1-(1H-imidazol-2-yl)ethanone 

Relevant academic research and scientific papers

A process for preparing 7-bromo imidazo [2,1-f] [1, 2, 4] triazin-4-amine method

The invention discloses a method for preparing 7-bromoimidazo[2,1-f][1,2,4]triazin-4-amine. According to the invention, a compound IX is adopted as a a raw material, and is subjected to a reaction with a compound X under the effect of alkali, such that a

Discovery of (S)-4-isobutyloxazolidin-2-one as a novel leucyl-tRNA synthetase (LRS)-targeted mTORC1 inhibitor

A series of leucinol analogs were investigated as leucyl-tRNA synthetase-targeted mTORC1 inhibitors. Among them, compound 5, (S)-4-isobutyloxazolidin-2-one, showed the most potent inhibition on the mTORC1 pathway in a concentration-dependent manner. Compound 5 inhibited downstream phosphorylation of mTORC1 by blocking leucine-sensing ability of LRS, without affecting the catalytic activity of LRS. In addition, compound 5 exhibited cytotoxicity against rapamycin-resistant colon cancer cells, suggesting that LRS has the potential to serve as a novel therapeutic target.

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF

Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

Acetohydroxamic acid: A new reagent for efficient synthesis of nitriles directly from aldehydes using Bi(OTf)3 as the catalyst

An efficient method for the preparation of nitriles directly from aldehydes by reaction with AHA using Bi(OTf)3 as the catalyst is described. Bi(OTf)3 is shown to be an efficient catalyst also for the conversion of aldoximes into nitriles.

5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)

The present invention relates to novel 5,6-dihydro-imidazo[1,2-a]pyrazin-8- ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, cerebrovascular amyloid angiopathy, multi- infarct dementia, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease or dementia associated with beta-amyloid.

PHENYL-3-{ (3- (1H- PYRROL- 2 -YL) - [1 , 2 , 4] 0XADIAZ0L-5-YL] PIPERIDIN-1-YL}-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS

The present invention provides new compounds of formula (I) as positive allosteric modulators of metabotropic receptors - subtype 5 ("mGluR5") which are useful for the treatment or prevention of central nervous system disorders such as for example, cognitive decline, both positive and negative symptoms in schizophrenia as well as other central or peripheral nervous system disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. The invention is also directed to pharmaceutical compounds and compositions in the prevention or treatment of such diseases in which mGluKi is involved. W represents (C4-C7)cycloalkyl, (C3-C7)heterocycloalkyl , (C3-C7)heterocycloalkyl-(C1-C3)alkyl or (C3-C7)heterocycloalkenyl ring; represents a (C5-C7)heteroeycloalkyl, (C5-C7)heterocycloalkeiiyl ring or a heteroaryl group of formula (a), (b), (c), (d), (e), (f), (g), (i). Q denotes a cycloalkyl, an aryl or heteroaryl group of formula (j), (k), (l), (m), (n). A is azo -N=N-, ethyl, ethenyl, ethynyl, -NR8C(=O)-, -NR8C(=O)-O-, -NR8C(=O)-NR9, NR8S(=O)2-, -C(=O)NR8-, -O-C(=O)NR8-, -S-, -S(=O)-, -S(=O)2-, -S(C=O)2NR8-, -C(=0)-0-, -0-C(=0)-, -C(=NR8)NR9-, C(C=NOR8)NR9- , -NR8C(=NOR9)-, =N-0-, -0-N=CH- or a group aryl or heteroaryl of formula, (o), (p), (q), (r), (s), (t), (u), (v), (w), (x). The other substituents are defined in the claims.

Biocidal composition

A biocidal composition containing, as active ingredients, at least one imidazole compound represented by formula (I): STR1 wherein R1 represents a phenyl group, a halogen-substituted phenyl group, an alkyl group, or a halogen-substituted alkyl group; and R2 represents a halogen atom, and at least one other specific compound. The combination of the compound represented by formula (I) and other specific compound can produce an unexpected effect in amount required and biocidal spectrum.

N-CYANO-N'-ALKYLIMIDAZOLIUM YLIDS AS NOVEL INTERMEDIATES TO 2-CYANOIMIDAZOLES

N-Substituted imidazoles were readily converted to 2-cyanoimidazoles by treatment with cyanogen chloride followed by triethylamine.The utilization of the SEM protecting group provided a facile entry to N-unsubstituted 2-cyanoimidazoles.